Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.

Gupta R, Balzer B, Picken M, Osunkoya AO, Shet T, Alsabeh R, Luthringer D, Paner GP, Amin MB.

Am J Surg Pathol. 2009 Feb;33(2):241-7. doi: 10.1097/PAS.0b013e318181b828.

PMID:
18941400
2.

Recent advances of immunohistochemistry for diagnosis of renal tumors.

Kuroda N, Tanaka A, Ohe C, Nagashima Y.

Pathol Int. 2013 Aug;63(8):381-90. doi: 10.1111/pin.12080. Review.

PMID:
23957913
3.

Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.

Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E.

Eur Urol. 2010 Jul;58(1):75-83. doi: 10.1016/j.eururo.2010.03.015. Epub 2010 Mar 23. Review.

PMID:
20359812
4.

Recent classification of renal epithelial tumors.

Kuroda N, Tanaka A.

Med Mol Morphol. 2014 Jun;47(2):68-75. doi: 10.1007/s00795-013-0033-0. Epub 2013 Mar 26. Review.

PMID:
23529139
5.

Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.

Oosterwijk E.

Subcell Biochem. 2014;75:181-98. doi: 10.1007/978-94-007-7359-2_10. Review.

PMID:
24146380
6.

Diagnostic approach to eosinophilic renal neoplasms.

Kryvenko ON, Jorda M, Argani P, Epstein JI.

Arch Pathol Lab Med. 2014 Nov;138(11):1531-41. doi: 10.5858/arpa.2013-0653-RA. Review.

7.

The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10.

Sangoi AR, Karamchandani J, Kim J, Pai RK, McKenney JK.

Adv Anat Pathol. 2010 Nov;17(6):377-93. doi: 10.1097/PAP.0b013e3181f89400. Review.

PMID:
20966644
8.

G250: a carbonic anhydrase IX monoclonal antibody.

Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA.

Curr Oncol Rep. 2005 Mar;7(2):109-15. Review.

PMID:
15717944
9.

Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment.

Tostain J, Li G, Gentil-Perret A, Gigante M.

Eur J Cancer. 2010 Dec;46(18):3141-8. doi: 10.1016/j.ejca.2010.07.020. Epub 2010 Aug 13. Review.

PMID:
20709527
10.

[Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology].

Sibony M, Vieillefond A.

Ann Pathol. 2008 Oct;28(5):381-401. doi: 10.1016/j.annpat.2008.07.009. Epub 2008 Oct 17. Review. French.

PMID:
19068393
11.

Renal cell carcinoma: Evolving and emerging subtypes.

Crumley SM, Divatia M, Truong L, Shen S, Ayala AG, Ro JY.

World J Clin Cases. 2013 Dec 16;1(9):262-75. doi: 10.12998/wjcc.v1.i9.262. Review.

12.

Biomarkers in renal cell carcinoma.

McGuire BB, Fitzpatrick JM.

Curr Opin Urol. 2009 Sep;19(5):441-6. doi: 10.1097/MOU.0b013e32832f0c68. Review.

PMID:
19584732
13.

Tissue-based molecular markers for renal cell carcinoma.

Rink M, Chun FK, Robinson B, Sun M, Karakiewicz PI, Bensalah K, Fisch M, Scherr DS, Lee RK, Margulis V, Shariat SF.

Minerva Urol Nefrol. 2011 Dec;63(4):293-308. Review.

PMID:
21996985
14.

Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma.

Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E.

Int J Mol Sci. 2013 May 29;14(6):11402-23. doi: 10.3390/ijms140611402. Review.

15.

Renal tumors: diagnostic and prognostic biomarkers.

Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel..

Am J Surg Pathol. 2013 Oct;37(10):1518-31. doi: 10.1097/PAS.0b013e318299f12e.

16.

Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas.

Rao Q, Xia QY, Cheng L, Zhou XJ.

Chin J Cancer Res. 2016 Feb;28(1):29-49. doi: 10.3978/j.issn.1000-9604.2016.01.03. Review.

17.

Tubulocystic oncocytoma of the kidney: a case study and review of literature with focus on implications for differential diagnosis.

Zhang Q, Ma J, Wu CY, Zhang DH, Zhao M.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14786-92. eCollection 2015 Nov 1. Review.

18.
19.

Next revolution in molecular theranostics: personalized medicine for urologic cancers.

Aoun F, Kourie HR, Artigas C, Roumeguère T.

Future Oncol. 2015;11(15):2205-19. doi: 10.2217/fon.15.104. Review.

PMID:
26235183
20.

Value of PAX 8 immunostaining in tumor diagnosis: a review and update.

Ordóñez NG.

Adv Anat Pathol. 2012 May;19(3):140-51. doi: 10.1097/PAP.0b013e318253465d. Review.

PMID:
22498579

Supplemental Content

Support Center